2024 Prediction from Jeffrey Casberg, M.S., RPh
Casberg is Vice President of Clinical Pharmacy at IPD Analytics LLC and a member of the Managed Healthcare Executive editorial advisory board. He predicts that "payers will tighten" in 2024.
We asked our readers and some members of our editorial advisory board to make predictions for 2024. Here's what Jeffrey Casberg, M.S., RPh had to say:
“There will be increased trend toward transparency in the pharmacy benefit management industry, but the net result will
likely be little or no savings to employers or government payers. Negotiated Medicare drug prices under the Inflation Reduction Act don’t go into effect until 2026. Even so, the prospect of negotiated prices will start to affect Medicare and commercial payers’ formulary management in 2024. This will be the second year that Humira (adalimumab) biosimilars will be on the market. Compared to some high year two expectations, uptake will be lower than even modest prediction.
With Wegovy (semaglutide) and Zepbound (tirzepatide) approved by the FDA and on the market, payers will be working to tighten glucagon-like peptide 1 (GLP-1) inhibitor coverage criteria in 2024 as utilization continues to ramp up. We’re also going to see increased pressure on federal and state payers to cover weight loss drugs.
The drug shortages have been a problem for several years, especially in the hospital space, and they will continue next year. It is a problem with many different causes. None of them yield to easy answers and they won’t be solved in 2024.”
Optimize Your Healthcare Payments with Optum Financial
April 29th 2025Discover how Optum Financial is revolutionizing healthcare payments in our latest whitepaper. Learn how transitioning to electronic payments can reduce administrative costs, streamline claims processing and enhance security.
Read More
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Healthcare hasn't been a priority of the second Trump administration so far, panelists at the Asembia agreed. Medicaid may loom large, though, as the administration and congressional Republicans look for ways to slash government spending as a way of offsetting major tax cuts.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
What 5 Managed Care Trends Experts Say You’re Not Watching Closely Enough
April 29th 2025Managed Healthcare Executive asked several experts in healthcare and managed care to share the trends they think the industry is overlooking. From rising costs and data challenges to shifts in how care is delivered, these are the issues that could have a major impact — and deserve a closer look.
Read More
